08.04.2025 • NewsVeranovaPeople

Veranova Appoints Scott Zugel as New Global VP

Veranova welcomes Scott Zugel as Global VP of Analytical Research Development Operations.

Veranova announces the appointment of Scott Zugel as Global Vice President of...
Veranova announces the appointment of Scott Zugel as Global Vice President of Analytical Research Development Operations. © Veranova

Zugel brings 25 years of experience in the chemical and pharmaceutical industries, with extensive expertise in the analytical development of small and large molecules. He is well-versed in developing and validating assay, purity, and dissolution methods for combination therapies containing multiple active pharmaceutical ingredient (API) formulations, with proven success in obtaining new drug application (NDA) approvals for a wide variety of drug indications.

Most recently, Zugel served as the Head of Analytical Development (USA) at Takeda Pharmaceuticals, where he led analytical activities across multiple sites and successfully merged legacy biologics and synthetic molecule analytical development teams into a cohesive department. He is also credited with centralizing Takeda’s GMP analytical testing labs and establishing the first internal metrology team. Before joining Takeda, Zugel spent seven years with Pfizer Global R&D, where he held several roles, ultimately becoming a Laboratory Leader.

Zugel holds a PhD in Analytical Chemistry from Purdue University and a BS in Chemistry from Valparaiso University. His contributions to the field are well-recognized, with multiple publications, numerous presentations, and long-standing membership in the Analytical Leadership Group in the IQ Consortium. He has also been honored by esteemed organizations such as Millennium and Pfizer and has completed fellowships with the Purdue Research Foundation Fellowship and the Brown-Wetherill Fellowship.

"We are delighted to welcome Scott Zugel as our Global Vice President of Analytical Development Operations," says Rohtash Kumar, Senior Vice President of Development Operations and Chief Technology Officer at Veranova. "His wealth of experience and track record of excellence make him a valuable asset to our team as we continue to advance our global R&D strategy and drive pharmaceutical success for our partners.".
 

Company

Logo:

Veranova

435 Devon Park Drive
19087 Wayne
US

Company contact







Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.